Eicosapentaenoic Acid Modulates TGF-β1/Smad3/ILK Pathway to Attenuate Renal Fibrosis: A Biotechnological Approach.
EPA shows preliminary potential as an antifibrotic agent in vitro by targeting the TGF-β1/Smad3/ILK pathway to regulate ECM remodeling and EMT suppression in renal fibrosis. This study provides insights into the EPA's application in medical biotechnology, particularly for CKD management.
Authors
- Juan Cao (ORCID: https://orcid.org/0000-0002-4333-2991)
- Haitao Li (ORCID: https://orcid.org/0000-0001-9160-8334)
- Hao Ding (ORCID: https://orcid.org/0000-0003-0774-4670)
- Di Yin (ORCID: https://orcid.org/0000-0002-3272-9643)
- Zhiqiang Wei (ORCID: https://orcid.org/0000-0003-1106-0087)
Institutions
- Taixing People's Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.30498/ijb.2025.513787.4098
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00